Nanotubes enable travel of Huntington’s disease protein

May 10, 2019

Jupiter, FL - A toxic protein linked to Huntington’s disease can move from neuron to neuron through a nanotube tunnel whose construction is initiated by a protein called Rhes, say scientists at Scripps Research.

The finding, by Scripps Research neuroscientist Srinivasa Subramaniam, PhD, improves understanding of how and why this disease attacks and destroys certain brain cells. The research was published Friday, May 10 in the Journal of Cell Biology.

Scripps Research Neuroscience Associate Professor Srinivasa Subramaniam, PhD, and research associate Manish Sharma, PhD, review confocal microscope images of the Huntington’s protein moving between neurons via nanotube.

“We are excited about this result because it may explain why the patient gets the disease in this area of the brain called the striatum,” says Subramaniam, an associate professor in the Department of Neuroscience at Scripps Research-Florida.

People with Huntington’s disease inherit a damaged protein that is somehow complicit in destroying brain cells. Scientists discovered this protein in 1993 but are still piecing together its role in this degenerative disease. Scans show Huntington’s disease brains are shrunken and degraded. As the neurons deteriorate, people lose motor control, they can have emotional problems and their thinking and memory suffer. Symptoms usually begin around age 30 to 40 and last 15 to 20 years until death. A rarer and more aggressive form of the disease affects children, cutting their childhood and lives short.

About 3 to 7 people out of 100,000 have the disease and it has mostly affected those with European ancestry. However, Subramaniam believes the disease is underreported in other areas, such as India. 

“There is a lot of stigma associated with the disease,” says Subramaniam.

His laboratory investigates the molecular mechanics of Huntington’s disease and other neurodegenerative illnesses, including Alzheimer’s and Parkinson’s disease, to find potential therapy targets.

“In the case of Huntington’s, the question is can we block this transport, and does it have any benefit or effect?” says Subramaniam.

For this study, Subramaniam and colleague Manish Sharma, PhD, looked at mouse neurons under a confocal microscope and saw that the cells formed sticky, string-like protrusions around 150 microns long which floated above the cells, connecting them. 

“When I saw Rhes making these tunnel-like tubes between the cells I was excited and at the same time perplexed,” says Sharma, the first author of the study.

“They may have been missed before because they are on a different plane,” says Subramaniam. “You have to be really looking for it. It’s like a bridge over a lake. If you are on the lake, you may not see the bridge above, but if you are on shore, you can see the bridge.” 

Scientists first described another type of tunneling nanotube in rat neurons in 2004. Since then, a number of researchers have observed them in cancer and other types of cells. But how they form and what they do was less clear.

To find out, Subramaniam and Sharma tracked cell cargo moving through this tunnel bridge. They inserted the Huntington human disease protein into the mouse brain cells, tagged it with fluorescence and then watched as it crossed over and crawled up to enter the neighboring cell. Once the tunnel delivered its shipment it released and sprang back. Lysosomes and endosomes, cellular cargo bins that transport cell pieces or waste, also travel these intercellular highways, Subramaniam says.

The Rhes protein exists in both mouse and human brains sick with Huntington’s disease.  Knocking out the Rhes gene in diseased mice results in less brain damage. In 2009 study, Subramaniam found that Rhes also alters the Huntington disease protein’s structure making it more toxic to brain cells.

“The Rhes protein makes its own road. That is what is surprising to us,” says Subramaniam. “But it not only transports itself. Once the road is made, many things can be transported.”

Subramaniam’s group continues to investigate what other proteins may be helping with tunnel construction and if other disease proteins move along these membranous highways. His laboratory is also developing ways to identify how the Huntington’s disease protein travels in the live brain.

The study, Rhes Travels from Cell to Cell and Transports Huntington Disease Protein Via TNT-like Cellular Protrusions,” was supported in part by a training grant in Alzheimer’s drug discovery from the Lottie French Lewis Fund of the Community Foundation for Palm Beach and Martin Counties, and from the National Institutes of Health NIH/NINDS R01-NS087019-01A1, NIH/NINDS R01-NS094577-01A1 and Cure for Huntington Disease Research (CHDI).

For more information, contact See More News